2020
DOI: 10.1111/hiv.12829
|View full text |Cite
|
Sign up to set email alerts
|

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation

Abstract: The aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes. MethodsWe identified people with viruses harbouring the M184V/I mutation in UK multicentre data sets who had treatment change/initiation within 1 year. We analysed outcomes of viral suppression (< 200 HIV-1 RNA copies/mL) and appearance of new major drug resistance mutations (DRMs) using Cox and Poisson models, with stratification by new drug… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 41 publications
(42 reference statements)
0
1
0
Order By: Relevance
“…Reasons behind viral suppression on DTG/NRTIs regimens in patients carrying M184V/I Firstly, 3TC or FTC are constituents of DTG-based regimens and continual use of either 3TC or FTC in presence of M184V has been shown to encourage viral suppression and also reduce emergence of additional DRMs (Campbell et al, 2005;Stirrup et al, 2020). M184V has been associated with significantly lower plasma viral RNA levels in AVANT 2 and AVANT 3 studies (Maguire et al, 2000).…”
Section: Dolutegravir In Treatment Experienced Patients With M184v/i ...mentioning
confidence: 99%
“…Reasons behind viral suppression on DTG/NRTIs regimens in patients carrying M184V/I Firstly, 3TC or FTC are constituents of DTG-based regimens and continual use of either 3TC or FTC in presence of M184V has been shown to encourage viral suppression and also reduce emergence of additional DRMs (Campbell et al, 2005;Stirrup et al, 2020). M184V has been associated with significantly lower plasma viral RNA levels in AVANT 2 and AVANT 3 studies (Maguire et al, 2000).…”
Section: Dolutegravir In Treatment Experienced Patients With M184v/i ...mentioning
confidence: 99%